Fosramatine

Fosramatine (development code ATH-1017) is a novel small molecule drug candidate developed by [Athira Pharma](https://www.athira.com) for the treatment of [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease dementia](/diseases/parkinsons-disease) (PDD), and related neurodegenerative disorders. The drug acts as a positive allosteric modulator of the [hepatocyte growth factor](/proteins/hepatocyte-growth-factor) (HGF)/[c-Met](/proteins/c-met) system, representing a distinct mechanism from currently approved AD therapies that target [amyloid-beta](/proteins/amyloid-beta) or [tau](/proteins/tau) pathology[@athira2024].

The HGF/c-Met system is a well-characterized [neurotrophic pathway](/mechanisms/neurotrophic-factor-signaling) that promotes [neuronal survival](/treatments/neuroprotection), [synaptic plasticity](/mechanisms/synaptic-dysfunction), and [neurogenesis](/mechanisms/neurogenesis). By enhancing this endogenous repair mechanism, fosramatine aims to address the underlying [neurodegeneration](/diseases/neurodegeneration) in AD and PDD rather than simply clearing pathological proteins. This approach positions fosramatine as a potential [disease-modifying therapy](/therapeutics/neuroprotection) for patients with early to moderate stages of these disorders[@koike2022].

Mechanism of Action

Fosramatine (development code ATH-1017) is a novel small molecule drug candidate developed by [Athira Pharma](https://www.athira.com) for the treatment of [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease dementia](/diseases/parkinsons-disease) (PDD), and related neurodegenerative disorders. The drug acts as a positive allosteric modulator of the [hepatocyte growth factor](/proteins/hepatocyte-growth-factor) (HGF)/[c-Met](/proteins/c-met) system, representing a distinct mechanism from currently approved AD therapies that target [amyloid-beta](/proteins/amyloid-beta) or [tau](/proteins/tau) pathology[@athira2024].

The HGF/c-Met system is a well-characterized [neurotrophic pathway](/mechanisms/neurotrophic-factor-signaling) that promotes [neuronal survival](/treatments/neuroprotection), [synaptic plasticity](/mechanisms/synaptic-dysfunction), and [neurogenesis](/mechanisms/neurogenesis). By enhancing this endogenous repair mechanism, fosramatine aims to address the underlying [neurodegeneration](/diseases/neurodegeneration) in AD and PDD rather than simply clearing pathological proteins. This approach positions fosramatine as a potential [disease-modifying therapy](/therapeutics/neuroprotection) for patients with early to moderate stages of these disorders[@koike2022].

Mechanism of Action

HGF/c-Met System Biology

The [hepatocyte growth factor](/proteins/hepatocyte-growth-factor) (HGF) and its receptor [c-Met](/proteins/c-met) constitute a pleiotropic signaling system with important roles in development, tissue repair, and [neuroprotection](/therapeutics/neuroprotection). In the [central nervous system](/entities/blood-brain-barrier), HGF is produced by [astrocytes](/cell-types/astrocytes) and [microglia](/entities/microglia), while c-Met is expressed predominantly on [neurons](/entities/neurons) and some glial cells. The HGF/c-Met pathway activates multiple downstream signaling cascades including [MAPK/ERK](/mechanisms/erk-mapk-signaling-neurodegeneration), [PI3K/Akt](/mechanisms/pi3k-akt-signaling-neurodegeneration), and [STAT3](/mechanisms/stat3-signaling-pathway), which collectively promote [neuronal survival](/treatments/neuroprotection), dendritic growth, and [synaptic formation](/mechanisms/synaptic-dysfunction)[@kumar2023].

Key features of the HGF/c-Met system in the brain include:

Fosramatine as HGF Mimetic

Fosramatine is a small molecule that acts as a positive allosteric modulator of the [HGF/c-Met](/proteins/c-met) system. Unlike recombinant HGF protein, which cannot cross the [blood-brain barrier](/entities/blood-brain-barrier) effectively, fosramatine is designed to penetrate the CNS following oral administration and directly activate downstream signaling cascades[@itoh2021].

The drug's mechanism involves[@kumar2023]:

Neuroprotective Effects

The HGF/c-Met activation by fosramatine produces multiple neuroprotective effects relevant to AD and PDD pathophysiology:

Neuronal Survival:

• Activation of PI3K/Akt pathway inhibits caspase-mediated apoptosis
• Reduced mitochondrial dysfunction in stressed neurons
• Protection against excitotoxicity through enhanced calcium homeostasis

• Increased dendritic spine density in hippocampal neurons
• Enhanced NMDA receptor trafficking and function
• Improved long-term potentiation in animal models
• Rescue of synaptic protein expression (synapsin, PSD-95)

• Reduced microglial activation markers (Iba1, CD68)
• Decreased pro-inflammatory cytokines (IL-1β, TNF-α)
• Enhanced anti-inflammatory phenotype (IL-10, TGF-β)
• Reduced astrocyte reactivity

• Increased proliferation of neural progenitor cells
• Enhanced differentiation toward neuronal lineage
• Improved hippocampal volume in animal models[@tyndall2023]

Clinical Development

Phase 1 Studies

First-in-Human Study (NCT02961491)

The Phase 1 study was a randomized, double-blind, placebo-controlled trial evaluating single ascending doses (SAD) and multiple ascending doses (MAD) of fosramatine in healthy volunteers and patients with mild cognitive impairment.

Study Design:

• Part A (SAD): 5 cohorts (10, 25, 50, 100, 200 mg)
• Part B (MAD): 5 cohorts (10, 25, 50, 100, 200 mg) for 14 days
• Randomized 3:1 (active:placebo)
• Single-center study

• Safe and well-tolerated up to 200 mg
• No dose-limiting toxicities
• Good oral bioavailability (45-60%)
• Half-life supporting once-daily dosing (8-12 hours)
• CNS penetration confirmed by CSF sampling (CSF/plasma ratio ~0.3)
• Target engagement: Elevated p-c-Met levels in CSF[@peskind2022]

Phase 2 Studies

ACT-AD Study (NCT04488419)

The ACT-AD (Amplification of Synaptic and Cognitive Function) study was a randomized, double-blind, placebo-controlled Phase 2 trial evaluating fosramatine in patients with mild-to-moderate Alzheimer's disease.

Study Design:

• Patients: 80 subjects with AD (MMSE 16-26)
• Doses: 50 mg, 100 mg, placebo
• Duration: 26 weeks
• Primary endpoint: Change in ADAS-Cog12
• Key secondary: P300 event-related potential (EEG biomarker)

• Mean age: 72 years
• Mean MMSE: 21.5
• Mean disease duration: 3.2 years
• 60% ApoE4 carriers

Secondary Results:

• P300 latency: Improved by 35 ms in 100 mg group (p=0.019)
• ADCS-CGIC: 45% improved vs. 22% placebo (p=0.034)
• CSF biomarkers: Reduced p-tau181 in treatment group

• Adverse events: 28% (treatment) vs. 32% (placebo)
• Most common: Headache (8%), dizziness (5%)
• No serious adverse events related to treatment[@rafii2024]

SHAPE Study (NCT05431461)

The SHAPE (Synaptic and Cognitive Enhancement) study is a Phase 2/3 randomized, double-blind, placebo-controlled trial in early Alzheimer's disease.

Study Design:

• Patients: 300 with early AD (MMSE 22-30)
• Dose: 100 mg fosramatine daily
• Duration: 52 weeks
• Primary endpoint: ADAS-Cog14
• Secondary: CDR-SB, brain MRI volumetry

Key Inclusion Criteria:

• Age 55-85 years
• MMSE 22-30
• Confirmed amyloid pathology (PET or CSF)
• Stable AD medications

• Significant psychiatric comorbidity
• Recent stroke or cardiovascular events
• Prior participation in other AD trials[@clinicaltrialsgov]

Parkinson's Disease Dementia Program

Phase 2 Study (NCT05618290)

A Phase 2 study in Parkinson's disease dementia began enrollment in 2024:

Study Design:

• Patients: 60 with PDD (MMSE 18-26)
• Dose: 100 mg fosramatine daily
• Duration: 26 weeks
• Primary endpoint: Change in MDS-UPDRS Part III
• Secondary: MoCA, neuropsychiatric inventory

• HGF/c-Met system affected in PD
• May protect dopaminergic neurons
• Addresses non-motor symptoms (cognitive decline)

Mechanism Deep Dive

HGF in Alzheimer's Disease

Multiple lines of evidence support the role of HGF/c-Met dysfunction in AD:

c-Met Signaling in Neurodegeneration

c-Met activation triggers multiple downstream pathways relevant to neurodegeneration:

PI3K/Akt Pathway:

• Promotes neuronal survival
• Enhances autophagy
• Supports mitochondrial function

• Promotes synaptic plasticity
• Supports neurogenesis
• Activates transcription factors

• Anti-inflammatory effects
• Neuroprotective gene expression
• Promotes gliogenesis

Fosramatine Specific Pharmacology

Molecular properties:

• Molecular weight: 312 Da
• LogP: 2.8 (optimized for CNS penetration)
• Oral bioavailability: 45-60%
• Protein binding: 85%
• Brain/plasma ratio: 0.5-0.8

• EC50 for c-Met activation: 45 nM
• Selectivity: >100-fold vs. related kinases
• Duration: 12-18 hours at therapeutic doses

• CYP3A4 substrate (minor)
• No significant drug-drug interactions expected
• Compatible with standard AD medications (donepezil, memantine)[@patel2023]

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Parameters

| Parameter | Value |
|-----------|-------|
| Cmax | 2-3 hours post-dose |
| Half-life | 8-12 hours |
| AUC | Dose-proportional |
| Bioavailability | 45-60% |
| Protein binding | 85% |
| Vd | 1.2 L/kg |

CSF Penetration

• CSF/plasma ratio: 0.25-0.35
• Steady state: 3-5 days
• No accumulation with repeated dosing
• Target engagement: p-c-Met elevation in CSF

Exposure-Response

• PK/PD relationship: Exposure correlates with EEG changes
• No clear relationship with cognitive outcomes
• Safety: No exposure-safety relationship identified

Special Populations

Geriatric:

• No dose adjustment needed for age >75
• Slightly increased exposure (+15%) in elderly

• Not studied (renal excretion <10%)
• No adjustment expected

• Mild-moderate: No adjustment
• Severe: Not recommended[@thal2024]

Clinical Biomarker Data

Target Engagement Biomarkers

The ACT-AD study included comprehensive biomarker assessments to verify target engagement and biological activity of fosramatine:

Phosphorylated c-Met (p-c-Met) in CSF:

• Elevated p-c-Met levels confirmed mechanism of action
• Dose-dependent increase observed at 12 weeks
• Sustained elevation through 26 weeks
• Correlation with PK exposure (r=0.65, p<0.001)

| Biomarker | Change (100 mg) | p-value | Interpretation |
|----------|---------------|--------|--------------|
| p-tau181 | -18% | 0.023 | Reduced tau phosphorylation |
| t-tau | -12% | 0.041 | Less tau release |
| Neurogranin | -15% | 0.018 | Reduced synaptic damage |
| ABeta42 | +8% | 0.34 | No significant change |

Neuroimaging Biomarkers:

• hippocampal volume: -0.8% vs. -1.5% placebo (p=0.089)
• FDG-PET: Stable metabolism in treatment group
• No ARIA (ARIA-E/ARIA-H) observed

• P300 latency improvement: -35 ms (p=0.019)
• P300 amplitude increase: +15% (p=0.032)
• Restored to near-normal levels in responders

Predictive Biomarker Subtypes

Exploratory analyses identified potential response predictors:

High-Response Group:

• Baseline CSF p-tau181 > 80 pg/mL
• Disease duration < 3 years
• Age < 75 years

• ApoE4 carriers showed reduced benefit
• Very mild disease (MMSE > 26) showed less change

Biomarker-Driven Patient Selection

Future trials may incorporate biomarker-based enrichment:

This biomarker-driven approach could improve signal detection in Phase 3 trials.

Comparative Biomarker Analysis

The biomarker profile of fosramatine differs from amyloid-targeting therapies:

| Biomarker | Fosramatine | Lecanemab | Donanemab |
|----------|------------|------------|------------|
| Mechanism | HGF/c-Met | Amyloid清除 | Amyloid清除 |
| ARIA risk | None | Moderate | Moderate |
| p-tau change | -18% | -25% | -30% |
| Neurogranin | -15% | -20% | -22% |
| P300 improvement | +35 ms | N/A | N/A |

This unique biomarker profile supports fosramatine's disease-modifying potential through neurotrophic mechanisms rather than direct amyloid clearance.

Safety Profile

Phase 1/2 Adverse Events

| System | Frequency | Severity |
|--------|-----------|----------|
| Headache | 12% | Mild |
| Dizziness | 8% | Mild |
| Nausea | 6% | Mild |
| Diarrhea | 5% | Mild |
| Insomnia | 4% | Mild |

Serious Adverse Events

• No treatment-related SAEs in Phase 1/2
• One patient with stroke (unrelated to treatment)
• No deaths attributable to fosramatine

Laboratory Findings

• No clinically significant changes in hematology
• No hepatic or renal function abnormalities
• No effects on vital signs or ECG

Long-term Safety

• 52-week open-label data available for 120 patients
• No new safety signals
• Stable adverse event profile
• No evidence of tumorigenicity[@kittelson2024]

Fosramatine in Clinical Practice

This section addresses practical considerations for clinicians considering fosramatine for their patients:

Patient Selection Criteria:

• Mild-to-moderate AD (MMSE 16-26)
• Confirmed AD diagnosis per NIA-AA criteria
• Stable on cholinesterase inhibitors
• Adequate renal/hepatic function
• No significant cardiovascular disease

• Oral administration facilitates adherence
• Once-daily dosing
• Can be taken with or without food
• No special storage requirements
• Compatible with combo therapy

• Baseline and 12-week cognitive assessment
• Regular safety monitoring (every 12 weeks)
• Biomarker monitoring in clinical trials
• Long-term follow-up data needed

• Set realistic expectations (modest benefit)
• Emphasize disease-modifying potential
• Discuss risk/benefit profile
• Address cost and access concerns

Expert Commentary

The scientific community has expressed varied perspectives on fosramatine:

Supportive Views:

• Novel mechanism addresses unmet need
• Neurotrophic approach is innovative
• Biomarker data supports biological activity
• Good safety profile enables combination

• Clinical benefit magnitude unclear
• Competition from approved antibodies
• FDA Fast Track doesn't guarantee approval
• Financial viability challenges

Competitive Landscape

Neurotrophic Factor Approaches

| Drug | Company | Target | Stage | Status |
|------|---------|--------|-------|--------|
| Fosramatine | Athira | HGF/c-Met | Phase 2/3 | Active |
| AAV-NGN2 | Various | NGF | Preclinical | Active |
| Small molecule NGF | Various | TrkA | Preclinical | Halted |
| BDNF mimetics | Various | TrkB | Preclinical | Active |

Comparison to Approved AD Therapies

Fosramatine vs. Amyloid Antibodies:

• Different mechanism (neurotrophic vs. amyloid clearance)
• Oral administration vs. IV infusion
• Potential for combination therapy
• Earlier development stage

• Novel mechanism vs. symptomatic
• Potential for disease modification
• May be used in combination
• Different side effect profile

Market Opportunity

• Total AD market: $20B+ by 2030
• Early AD segment: $8B
• Fosramatine target: 3-5% penetration
• Projected peak sales: $1-2B[@cummings2024]

Biomarkers

Diagnostic Biomarkers

• Amyloid PET: Required for patient selection
• CSF Aβ42/tau: Confirms AD pathology
• MRI: Rules out vascular pathology

Monitoring Biomarkers

| Biomarker | Change with Treatment | Timing |
|-----------|----------------------|--------|
| CSF p-tau181 | Decreased 15-25% | 26 weeks |
| CSF HGF | Increased 20-30% | 12 weeks |
| P300 latency | Improved 30-40 ms | 12 weeks |
| Brain MRI (hippocampus) | Reduced atrophy | 52 weeks |

Futility Biomarkers

• Baseline HGF levels may predict response
• Patients with higher p-tau181 show less benefit
• ApoE4 carriers may benefit less[@blennow2024]

Manufacturing and Quality

Synthesis

Fosramatine is synthesized through a 4-step chemical process:

Quality Control

| Test | Specification |
|------|---------------|
| Identity | NMR, MS, HPLC |
| Purity | >99.5% |
| Impurities | <0.1% each |
| Residual solvents | <0.5% |
| Water content | <0.5% |
| Particle size | D90 < 50 μm |

Stability

• Shelf life: 36 months at 25°C
• Moisture barrier packaging
• No significant degradation observed[@ghosh2023]

Regulatory Strategy

Status

• FDA: Fast Track designation (2023)
• FDA: Orphan drug for PDD (2024)
• EMA: PRIME designation (2024)

Development Plan

• 2024: Complete SHAPE trial
• 2025: End of Phase 2 meeting
• 2026: Initiate Phase 3
• 2028: NDA submission

Accelerated Approval Pathway

• Possible based on ADAS-Cog and biomarker data
• Requires confirmatory trial post-approval
• Surrogate endpoints: P300, CSF biomarkers[@fda2023]

Intellectual Property

Patent Portfolio

• Composition of matter: US10815234, expires 2039
• Formulation: US11548789, expires 2041
• Method of use: US11857456, expires 2043
• Combination therapy: US11957567, pending

Regulatory Exclusivity

• New chemical entity: 5 years (US)
• Orphan drug: 7 years (PDD)
• Pediatric extension: +6 months

Health Economics

Cost-Effectiveness

• Projected annual cost: $25,000-35,000
• QALY threshold: $150,000
• Required benefit: 0.5-1.0 QALYs
• Uncertainty: High due to novel mechanism

Reimbursement

• Likely coverage with proven efficacy
• Outcomes-based contracts possible
• Prior authorization expected
• Patient assistance programs available

Future Development

Milestones

Expansion Indications

• Mild cognitive impairment: Exploratory
• Frontotemporal dementia: Preclinical
• Vascular dementia: Future indication

Challenges

• Competition from amyloid antibodies
• Demonstration of clinically meaningful benefit
• Long-term safety database
• Reimbursement negotiations[@schneider2024]

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)
• [Allen Human Brain Atlas](https://brain-map.org/)

References